Search Results
Sep 09, 2026, 02:00 ET Broadridge Launches DLX, an Always-On Digital Asset Infrastructure Platform for Tokenized Markets
transactions, DLX extends Broadridge's tokenization infrastructure into a broader, multi-asset platform for issuance, trading, settlement, servicing, custody, governance, and distribution. By connecting tokenized workflows and a growing partner network with established market systems, DLX helps
More news about: Broadridge Financial Solutions, Inc.
Aug 03, 2026, 08:58 ET Joie Expands into Canada, Bringing Globally Trusted Baby Gear to More Families
ginger™: A height-adjustable pramette stroller with a built-in lie-flat newborn mode that converts as your child grows.ginger™ dlx: An all-terrain 4-in-1 pramette stroller featuring puncture-proof tires and one-hand conversion for everyday adventures.nutmeg™: A
More news about: Joie
May 28, 2026, 11:32 ET NeuLogiq® Platform Helps Confirm No Evidence of Psychotomimetic, Hallucinatory, or Dissociative Effects in a Phase 1b Study of a Novel Neuroplastogen Developed for Major Depressive Disorder
(MDD). Preclinical data have demonstrated that DLX-001 increases dendritic spine density in neurons in the prefrontal cortex and has rapid and enduring antidepressant-like effects in animal models after a single dose. Recent Phase I data have demonstrated that DLX-001 is associated with robust signs of CNS
More news about: Cumulus Neuroscience
Oct 13, 2025, 04:00 ET Cumulus Neuroscience Presents Data at the International Society for CNS Clinical Trials and Methodology Autumn Conference and the 38th European College of Neuropsychopharmacology Congress
evaluating the pharmacodynamics, safety, and tolerability of a novel neuroplastogen, DLX-001, in people with MDD. The Phase 1b study was designed to show early evidence of target engagement and neuroplastic effects of DLX-001 in patients with MDD, and used the proprietary NeuLogiq Platform to gather data
More news about: Cumulus Neuroscience
Oct 06, 2025, 08:30 ET Neuropsychiatry Clinical Trials: Evolving with Portable EEG and Digital Endpoints, Upcoming Webinar Hosted by Xtalks
DLX-001 (zalsupindole) is a clinical-stage, novel neuroplastogen, in development for the treatment of major depressive disorder and illustrates the evolving
More news about: Xtalks